<DOC>
	<DOCNO>NCT01330355</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy Besivance ( besifloxacin 0.6 % ) ophthalmic suspension compare gatifloxacin 0.3 % ophthalmic solution administer three time daily ( TID ) seven day neonatal subject 31 day young day randomization ( Visit 1 ) .</brief_summary>
	<brief_title>Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution Neonates With Bacterial Conjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Bacterial</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Gatifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>7- ( 3-aminohexahydro-1H-azepin-1-yl ) -8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Subjects clinical diagnosis acute bacterial conjunctivitis exhibit conjunctival discharge redness least one eye . A minimum score 1 present discharge minimum score 1 conjunctival hyperemia eye . Subjects conjunctivitis sign and/or symptom suggestive fungal , protozoal , viral etiology either eye . Subjects require expect require ( study medication ) use topical ocular medication either eye , systemic medication course study prior Day 1 specify protocol ineligible . Subjects abnormality ocular anatomy ocular disease/disorder specify protocol ineligible . Subjects systemic disease/disorder specify protocol ineligible . Subjects know suspected poor tolerance , sensitivity , allergy study medication component . Subjects condition situation investigator 's opinion may impact safety would negatively affect conduct outcome study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>31 Days</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Ocular infection , bacterial</keyword>
</DOC>